This approval of durvalumab marks the first and only perioperative immunotherapy regimen available in muscle-invasive bladder ...

The FDA has approved neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab after radical cystectomy in MIBC.

The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in ...

AstraZeneca AZN recently announced that the European Commission has approved its blockbuster cancer drug Imfinzi (durvalumab) ...

Updated results from the NIAGARA trial further support perioperative durvalumab and neoadjuvant chemotherapy as a potential new treatment for patients with muscle-invasive bladder cancer, according to ...

Tremelimumab has been approved by the FDA in the US for use in tandem with AZ's PD-L1 inhibitor Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma (HCC), the most ...

IMFINZITM (durvalumab) has received approval in the European Union as a monotherapy for treating adults with limited-stage ...

Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...

Please note that following on from information provided to NICE by the company in February 2024 the appraisal was suspended from NICE’s work programme. As no further information has been received from ...

Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736] Technology appraisal guidance Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of ...